insulin aspart sanofi
sanofi winthrop industrie - inzulín aspart - cukrovka - lieky používané pri cukrovke - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
kirsty (previously kixelle)
biosimilar collaborations ireland limited - inzulín aspart - cukrovka - lieky používané pri cukrovke - kirsty is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastické činidlá - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
wegovy
novo nordisk a/s - semaglutide - obesity; overweight - prípravky proti obezite, okrem diétne výrobky - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to.
truvelog mix 30
sanofi winthrop industrie - inzulín aspart - cukrovka - lieky používané pri cukrovke - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.
inpremzia
baxter holding b.v. - insulin human (rdna) - cukrovka - lieky používané pri cukrovke - inpremzia is indicated for the treatment of diabetes mellitus.
lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastické činidlá - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
feiba 50 u/ml
baxalta innovations gmbh, rakúsko - faktor viii - inhibítor bypassovej aktivity - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
feiba 25 u/ml
baxalta innovations gmbh, rakúsko - faktor viii - inhibítor bypassovej aktivity - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
oxsoralen
g.l. pharma gmbh, rakúsko - metoxsalén - 42 - chemotherapeutica (vratane tuberkulostatik)